Philogen S.p.A., a clinical-stage biotechnology company, announced that France's National Agency for the Safety of Medicines and Health Products (ANSM) has authorized the company to run a phase II study of Nidlegy in patients affected by different non-melanoma skin cancer indications. A favourable opinion about the study had already been obtained by one of the country's ethic committees (Comit
